Detalhe da pesquisa
1.
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study.
Future Oncol
; 19(23): 1601-1611, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37577810
2.
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial.
Lancet Oncol
; 23(7): 876-887, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35636444
3.
KDR genetic predictor of toxicities induced by sorafenib and regorafenib.
Pharmacogenomics J
; 22(5-6): 251-257, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35484400
4.
Plasma levels of VEGF-A and VCAM-1 as predictors of drug-induced hypertension in patients treated with VEGF pathway inhibitors.
Br J Clin Pharmacol
; 88(9): 4171-4179, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35437784
5.
CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies.
Br J Cancer
; 125(6): 839-845, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34253871
6.
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
Oncologist
; 26(4): 302-309, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33336844
7.
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Lancet Oncol
; 21(4): 497-507, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32164906
8.
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials.
Br J Cancer
; 123(3): 403-409, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32424148
9.
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
BMC Cancer
; 20(1): 683, 2020 Jul 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-32698790
10.
Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib.
Pharmacogenomics J
; 19(5): 455-464, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30686821
11.
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.
Br J Cancer
; 118(7): 955-965, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29531324
12.
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients.
Invest New Drugs
; 36(4): 709-714, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29488048
13.
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer.
Br J Cancer
; 116(3): 318-323, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28081548
14.
TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.
BMC Cancer
; 17(1): 408, 2017 Jun 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28599628
15.
Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer.
Oncologist
; 21(8): 988-94, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27382031
16.
Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
Int J Cancer
; 136(1): 83-90, 2015 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24806288
17.
Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope.
Oncologist
; 20(11): 1261-5, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26446234
18.
Mapping the landscape of immunonutrition and cancer research: a comprehensive bibliometric analysis on behalf of NutriOnc Research Group.
Int J Surg
; 110(1): 395-405, 2024 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37737933
19.
Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials.
Eur J Cancer
; 184: 106-116, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36913832
20.
Clinical nutrition in surgical oncology: Young AIOM-AIRO-SICO multidisciplinary national survey on behalf of NutriOnc research group.
Front Nutr
; 10: 1045022, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37125048